VERAVera Therapeutics, Inc.
$29.87+17% 1Y
$29.87
$24.1052 weeks$55.67
VERA as reported
- Net income
- −$402M
Net income · +84% year on year · trailing twelve months to Q2 2026
- Free cash flow
- −$339M
Free cash flow · +82% year on year · trailing twelve months to Q2 2026
- EPS
- −$5.86
EPS · +64% year on year · trailing twelve months to Q2 2026
Details›
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net income | −$402M | +84% | Q2 2026 |
| EPS | −$5.86 | +64% | Q2 2026 |
| ROE | −71% | n/a | Q2 2026 |
| ROA | −56% | n/a | Q2 2026 |
| ROIC | 1252% | n/a | Q2 2026 |
| Free cash flow | −$339M | +82% | Q2 2026 |
Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.
Vera Therapeutics, Inc. (VERA) · Net incomeNet incomeVera Therapeutics, Inc. (VERA)
On our screens:Most shorted stocks